Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Taltz’s Nr-axSpA approval not enough to beat Cosentyx in axSpA

Despite receiving Food and Drug Administration (FDA) approval for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) before Novartis’s Cosentyx (secukinumab), Eli Lilly’s Taltz (ixekizumab) will not overthrow Cosentyx as the premiere anti-interleukin (IL) 17 biologic in the axSpA space. Taltz is forecast to achieve 2028 sales of $239m across the seven major markets (7MM*), whereas […]
Read more

Results from study show oral selexipag for PAH effective and safe in children, says GlobalData

Oral selexipag could improve treatment for the pediatric population based on its convenient administration, better safety and better tolerability profile compared to currently available options according to GlobalData, a leading data and analytics company. Selexipag is the only prostacyclin receptor agonist approved to target the prostacyclin pathway in adults with PAH, and is indicated for […]
Read more

Increasing number of hydroxychloroquine clinical trials for COVID-19 treatment will be withdrawn or terminated

Hydroxychloroquine may have resulted in a large amount of wasted effort towards finding a treatment for COVID-19 as another hydroxychloroquine study has shown no benefits of using the anti-malarial drug to treat COVID-19. This is bad news for the 398 COVID-19 clinical trials using hydroxychloroquine and/or chloroquine as a primary or secondary intervention, says GlobalData, […]
Read more

Latin America has not yet reached peak COVID-19 cases, says GlobalData

Latin American countries are showing dangerous trends of increasing COVID-19 cases. Brazil, Peru, Chile, and Mexico are now ranked second, tenth, thirteenth, and fourteenth, respectively, in the number of COVID-19 cases. GlobalData forecasts that these markets have not yet reached peak case numbers. It is likely that the outbreak will continue to worsen in Latin […]
Read more

Machine learning can aid in COVID-19 epidemiology, says GlobalData

As the COVID-19 pandemic continues to evolve across the globe, a large amount of data on its epidemiology has been generated. Finding relationships and predictive factors in this data can be aided by the application of machine learning and neural networks to find complex patterns in the data more efficiently and help predict the future […]
Read more

Future of over 320 hydroxychloroquine trials is now uncertain, says GlobalData

Following today’s news (Monday 15 June) that the FDA has pulled emergency use authorization of hydroxychloroquine for COVID-19; Johanna Swanson, Product Manager at GlobalData, a leading data and analytics company, offers her view: “GlobalData expects the number of withdrawn or terminated hydroxychloroquine clinical trials will increase in the coming month. This news leaves an uncertain […]
Read more

COVID-19 accelerates innovations in pharma industry and FDA, says GlobalData

The global COVID-19 pandemic has become a catalyst for the pharma industry and the US Food and Drug Administration (FDA) to implement long-awaited innovations. The urgent manufacturing needs caused by the pandemic and the requirement for social distancing are driving pharma companies and regulators to finally deploy advanced technologies that have been suggested for years […]
Read more

Generic remdesivir may put pricing pressure on Indian pharma companies, says GlobalData

Following the news that the Indian state of Maharashtra is planning to procure Gilead Sciences’ antiviral drug remdesivir from Bangladesh-based pharmaceutical giant Eskayef Pharmaceuticals; Anupama Mishra, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view: “Maharashtra is the worst affected state of the COVID-19 outbreak in India. The state has reported […]
Read more

Immunotherapies may increase risk of severe COVID-19 in MS patients as total MS drug market in the 7MM set to reach $32.9bn by 2028

COVID-19 presents a challenge to physicians managing patients with multiple sclerosis (MS), due to concerns about using immunotherapies to treat this neurological condition, in the face of the pandemic, says GlobalData, a leading data and analytics company. Immunotherapies are the biggest driver in the MS market and according to GlobalData’s report, ‘Multiple Sclerosis – Global Drug Forecast […]
Read more
1 … 88 89 90 91 92 … 108